Objectives. To estimate the incidence, characteristics and predictors of infections in patients with PM and DM.
Introduction
PM and DM are systemic inflammatory disorders that affect the skeletal muscles and other internal organs. PM and DM are associated with high morbidity and mortality rates. The 5-year survival rates for these patients range from 52 to 95%, and primary causes of death are related to cardiac, pulmonary and cancer involvement, as well as infectious manifestations [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Several predisposing factors in PM/DM patients increase their risk of developing infections. These factors include upper oesophageal involvement, thoracic muscle myopathy, use of immunosuppressive drugs and immune system dysfunction due to PM/DM itself [4, 5, 7, [11] [12] [13] . The literature indicates that, not only do PM/DM patients have a high rate of infectious complication (up to 33%) [13] , infection is also implicated in 46% of deaths in this patient group, which makes it a significant prognostic factor [13] .
Given the impact of infectious complications on PM/DM patients, this retrospective study was performed to characterize the clinical features of infectious diseases associated with PM/DM. The medical records of 192 PM/DM patients treated at a single medical centre were reviewed.
The research project was reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital. The aims of this study were: (i) to investigate the incidence, characteristics and outcomes of infections in PM/DM patients; and (ii) to assess the differences between patients with and without infections regarding clinical and biochemical features to detect patients at risk for infections.
Materials and methods

Study population
This study analysed 192 patients diagnosed with PM (n = 79) or DM (n = 113). All patients were treated at Chang Gung Memorial Hospital, a tertiary teaching medical centre in Taiwan that treats 4 million outpatients and 150 000 inpatients annually. The study was approved by the Institutional Review Board at this institution (96-0573B, 97-2070B). Written informed consent was not obtained from each patient due to its retrospective chart review nature. All diagnoses of PM/DM were made between January 1999 and December 2008 using criteria proposed by Bohan and Peter in 1975 [14] . The patients were further categorized into four main groups: Group I, primary idiopathic PM; Group II, primary idiopathic DM; Group III, juvenile PM/JDM; and Group IV, amyopathic DM (ADM) [15] . Juvenile PM/JDM was defined as PM/ DM onset at 417 years of age [16] . ADM was diagnosed by typical DM rash (heliotrope rash or Gottron papules), lack of muscle weakness and normal creatine phosphokinase (CPK) [17] .
Data collection
The medical records of 192 eligible subjects were reviewed from the time of diagnosis until death, loss to follow-up or the end of the study period. Collected data included age at onset, gender, clinical features at presentation, laboratory test results from the first encounter, complications, associated CTDs and associated malignancies. Details of PM/DM therapy regimen and any history of steroid/cytotoxic therapy were carefully noted. Treatment with methylprednisolone pulse and IVIG was presented as courses. Oral steroid (prednisone equivalent) therapy and other cytotoxic drugs (MTX and AZA) were analysed for mean daily dose and cumulative dose, i.e. the mean daily dose multiplied by total days of treatment calculated as described by Stuck et al. [18] .
Definitions
Patients were designated as having infectious complications by means of supportive clinical features and positive cultures and/or response to antibiotic therapy. Microbiologically documented infection was defined as signs or symptoms of infection with an organism isolated from a blood culture, histological material or definite site of infection. Clinically documented infection was defined as fever accompanied by appropriate clinical findings such as pulmonary infiltrates or inflammation of the skin or soft tissue [19] .
A major infection was defined as one that necessitated the use of i.v. and/or prolonged course of anti-microbial agents of duration >1 week [20] . Observed major infections included urinary tract infection, pneumonia, deepseated soft-tissue infection such as abscesses and necrotizing fasciitis, bacteraemia, tuberculosis and invasive fungal infection. Viral infections were recorded if they could be confirmed by high titres of antibodies for virus-specific antigens or compatible tissue findings. The number, types and sites of major infectious episodes and the respective micro-organisms were entered into our database. Minor infections, which were mostly selflimiting, including upper respiratory infections, gastroenteritis, superficial skin infections and oral mucosal infections, usually do not involve hospital admission and were excluded from the analysis as the data collection was incomplete.
Nosocomial infections were defined according to Center for Disease Control (CDC) criteria [21] . Opportunistic organisms were indicated by Cohen classification [22] , which is based on the principles proposed by von Graevenitz [23] . Polymicrobial infection was defined as a concomitant isolation of two or more species from the same culture or isolations from two different cultures within 24 h.
Statistical analysis
Numerical data were presented as means (S.D.), while categorical data were expressed as absolute frequencies and percentages. Either chi-squared test or Fisher's exact test was used as needed for group comparisons of categorical data. Two-tailed Student's t-test or nonparametric Mann-Whitney U-test was used for group comparisons of numerical data. The results were considered statistically significant if P < 0.05. Additionally, multivariate analysis was performed using logistic regression to identify independent risk factors for major infection. The odds ratio (OR) was presented with a 95% CI. Finally, cumulative survival rates were calculated by Kaplan-Meier method. All statistical calculations were performed using SPSS 12.0 software (SPSS, Chicago, IL).
Results
Patient demographics
In the 192 PM/DM patients (64 males, 128 females) in this study, mean age at PM/DM onset was 47.2 (18.6) years. The mean duration of follow-up was 3.6 (3.1) years. DM was the most common type [n (%) = 94 (49. Table 2 shows the anatomic site of major infections and the isolated micro-organism. Pulmonary infection, including 16 cases of aspiration pneumonia indicated by documented medical history of choking, was the most common infection [n (%) = 30 (39.5)], followed by soft-tissue infection [n (%) = 13 (17.1)], urinary tract infection [n (%) = 9 (11.8)] and bacteraemia without focus [n (%) = 8 (10.5)]. Of the 76 major infectious episodes, 10 were not microbiologically documented. The organisms detected during the remaining 66 episodes included 57 (86.4%) bacterial, 6 (9.1%) viral and 3 (4.5%) fungal organisms. Seven episodes (9.2%) of major infections were polymicrobial. Twenty-three species of pathogens were isolated from 53 PM/DM patients who had suffered from major infections. The most common micro-organisms infecting the PM/DM patients were Staphylococcus aureus and Klebsiella (15.3% each) followed in frequency by Escherichia coli (9.7%), Mycobacterium (9.7%) and Salmonella (8.3%).
Opportunistic infections comprised 18.4% of all infectious episodes. Six patients who developed M. tuberculosis infections included four with pneumonia, one with meningoencephalitis, and one with spondylodiscitis. One patient developed septic arthritis due to Mycobacterium avium intracellulare. CMV diseases were identified in four patients: two had CMV antigenaemia, one had CMV antigenaemia with hepatitis and one had CMV pneumonitis. The only three invasive fungal infections consisted of two cases of Candida albicans (one of the lung and one of the oesophagus) and one case of cryptococcal pneumonia. 
Univariate analysis of major infection predictors
Based on the clinical data, an older age at onset was apparent in patients who developed major infections (52.3 vs 45.3 years; P = 0.019; Table 3 ). The incidence of arthritis/ arthralgia (47.2 vs 26.6%; P = 0.006) and dysphonia (20.8 vs 7.2%; P = 0.007) was higher in the infected group than in the non-infected group. The prevalence of interstitial lung disease (ILD) was higher in patients with major infections than in those without (49.1 vs 10.8%; P < 0.001). The infected and non-infected PM/DM patients did not significantly differ in gender or incidence of dysphagia, RP, associated CTDs or malignancy.
Comparisons of biochemical variables showed that patients with major infections had lower peripheral blood absolute lymphocyte count (1244.3 vs 1587.9 counts/mm 3 ; P = 0.010) and more frequent presence of anti-Jo-1 antibody (19.4 vs 5.3%; P = 0.037) than those without infections. However, haemoglobin, platelet, leucocyte count, CPK, ESR and the prevalence of positive ANA did not differ in patients with major infections compared with those without.
As to PM/DM therapy regimen, use of AZA (56.6 vs 30.9%; P = 0.001) and IVIG (20.8 vs 3.6%; P < 0.001) was significantly associated with major infections. No significant difference was found between the infected and non-infected groups with regard to following: mean daily doses of steroids (25.8 vs 21.2 mg prednisone equivalents; P = 0.376), cumulative doses of steroids (15.1 vs 11.4 g prednisone equivalents; P = 0.062), mean daily doses of AZA (71.7 vs 64.6 mg; P = 0.071), mean cumulative doses of AZA (26.0 vs 34.7 g; P = 0.077), mean weekly doses of MTX (9.7 vs 8.4 mg; P = 0.452), mean cumulative doses of MTX (330.0 vs 495.0 mg; P = 0.694), mean courses of methylprednisolone pulse (1.4 vs 1.1; P = 0.075) and mean courses of IVIG (2.6 vs 1.6; P = 0.219). In the infection group, steroid mean daily dose over total study period vs steroid dose at the time of infection was 24.6 (16.3) vs 32.8 (25.4) mg/day (paired t-test P = 0.001).
Multivariate analysis of major infection predictors Several significant factors were selected for logistic regression analysis to identify independent predictive factors for major infections in PM/DM patients (Table 4) . These factors included mean age at onset, gender, arthritis/arthralgia, dysphonia, ILD, peripheral blood absolute lymphocyte count, AZA and IVIG. Although univariate analysis indicated that anti-Jo-1 antibody was statistically 
Survival analysis
Of the 192 PM/DM patients, 36 (18.8%) died during the follow-up period. The Kaplan-Meier survival curves show the survival probability for patients with (n = 53) and without (n = 139) major infection (Fig. 1) . Since PM/DM diagnosis, the overall survival of our cohort was 85.0% at 1 year, 78.0% at 5 years and 78.0% at 10 years. However, after the first episode of major infection, survival declined sharply to 84.7% at 30 days and 68.3% at 1 year. Twenty patients died during the follow-up period in the infected group. Directly attributable causes of death in the infected group were infection in 15 (75%) patients, respiratory muscle weakness in 2, ILD progression in 1, lung cancer in 1 and cardiovascular complication in 1.
Discussion
Infectious complications have been frequently reported in patients with CTDs. Many factors, e.g. disordered immune response and immunosuppressive medications employed, have been mentioned to account for the elevated frequency of infections in these patients [11, 24, 25] . However, more attention has been paid to patients with SLE and RA in the past decades [26] . Few reports were published before this study concerning PM/DM patients was undertaken. Compared with other studies, this study revealed a similar percentage of PM/DM patients complicated by infectious diseases (27.6%). Aspiration pneumonia caused by Gram-positive and anaerobic bacteria was the most common infection in PM/DM patients, which is also consistent with previous studies [4, 11, 13, 29] . Notably, aspiration pneumonia is not only the most common infection type, but it is also the main cause of death in patients with PM/DM [4, 13, 29] . In a study by Marie et al. [4] , aspiration pneumonia accounted for 30% of all mortalities. Similarly, of the 36 patients who died in this series, 9 (25%) died of aspiration pneumonia. Therefore, PM/DM patients who have oesophageal motor involvement and ventilatory insufficiency, which are risk factors for aspiration pneumonia, were recommended to be diagnosed early and treated aggressively to decrease the probability of a fatal outcome [4, 11, 13, 29] .
The large patient population in this study enabled reliable characterization of numerous species that cause major infections. Our results provide a basis for empirical selection of antibiotics for PM/DM patients with clinical symptoms/signs of major infection. In this study, the most common (86.4%) major infections were bacterial. Specifically, S. aureus, Klebsiella, E. coli and Salmonella accounted for 48.6% of all infections. Therefore, we suggest empiric antibiotic therapy against S. aureus, Klebsiella, E. coli and Salmonella species in Asian PM/ DM patients with suspected major infections.
Previous reports indicate that opportunistic infections occur in 10.9-21.3% of PM/DM patients [13, 27, 28, 30] . Of the 192 PM/DM patients analysed in this study, 12 (6.3%) had 14 episodes (including 2 patients with 2 episodes each) of opportunistic infection. Among the opportunistic infections, Mycobacterium was the most commonly isolated organism and accounted for half of the opportunistic infectious episodes: four cases of pulmonary tuberculosis and three cases of extrapulmonary infections produced by Mycobacterium tuberculosis and Mycobacterium avium intracellulare. The co-existence of mycobacterial infection and PM/DM has been described in previous investigations [31] [32] [33] [34] [35] , including some reports from countries in which tuberculosis is not endemic [33] [34] [35] . Considering the endemic nature of tuberculosis in Taiwan as well as the strong association of mycobacterial infections with PM/DM observed in this study, the possibility of mycobacterial infection has to be kept in mind when diagnosing and treating patients with myositis [35] . Four patients in this series had CMV infections, which constituted the second most common pathogen among opportunistic infections. A few CMV infections, including some severe and fatal infections such as interstitial pneumonia, have been reported in PM/DM patients [36] [37] [38] . In a recent multicentre survey of 151 patients with rheumatic diseases and CMV infections [39] , 15 (10.1%) patients had DM and 7 (46.7%) of the 15 DM patients died. Our findings also indicate the severity of CMV in PM/DM: one patient required mechanical ventilation at diagnosis and one died of septic shock.
Regarding fungal infection, Pneumocystis jirovecii pneumonia played an important role in PM/DM patients in earlier studies [11, 13, 30, [40] [41] [42] . Godeau et al. [40] estimated that the incidence of P. jirovecii pneumonia is as high as 20 per 10 000 patient-years in PM/DM. Marie et al. [13] and Viguier et al. [30] also reported that P. jirovecii pneumonia was responsible for 16.7 and 50.0% of opportunistic infections in PM/DM patients, respectively. Unlike other studies, the current series study revealed no cases of P. jirovecii pneumonia throughout the study period. The reason for the discrepancy between this study and previous reports is not clear, but it may be due to the fact that Taiwan is not an endemic country. Since Taiwan is not an endemic area of P. jirovecii, none of the patients received prophylactic antibiotics for pneumocystis pneumonia (PCP). There are no published guidelines for PCP prophylaxis among patients with rheumatological diseases receiving immunosuppressive drugs, but some advocate its use in patients when they are receiving high-dose immunosuppressive therapy in high endemic areas [30, 41] . Candidiasis is another fungal infection that has been mentioned to account for a considerable number of opportunistic infections in patients with CTDs [11, 13, 43, 44] . In the present study, C. albicans, which causes oesophageal and lung infections, was responsible for 14.3% of opportunistic infections in the analysed PM/DM patients.
Reported survival of PM/DM patients is 72-95% at 1 year, 52-95% at 5 years and 53-89% at 10 years [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . In the present study, the cumulative survival rates were 85.0% at 1 year, 78.0% at 5 years and 78.0% at 10 years, which is consistent with other recent studies [5] [6] [7] 9 ]. In the current study, however, PM/DM patients who had experienced at least one episode of major infection had a 1-year cumulative survival rate of only 68.3%, which indicates that PM/DM patients with major infections have a poorer prognosis than the general PM/ DM population does. In this population, these data highlight the need for early recognition and prompt treatment for infections, particularly aspiration pneumonia and opportunistic infections [4, 11, 13, 29, 39] . Predictors of infections are always a concern in PM/DM patients, given their associations with morbidity and mortality. A widely recognized infection risk factor in patients with CTDs is the use of immunosuppressive agents [11, 13, 30, 42, 45] . Among these agents, steroid is by far the most widely discussed in the literature. In a meta-analysis of 71 trials involving over 2000 patients with different diseases, the relative risk of infection was higher (1.6; 95% CI 1.3, 1.9) in patients who had been treated with steroids, than in those who had not [18] . Two other studies of PM/ DM patients also demonstrated that systemic CS therapy and high mean daily doses of steroids were associated with increased risk of herpes virus and opportunistic infections, respectively [13, 46] . Interestingly, we found that the use of steroid therapy, including mean daily doses and cumulative doses, were not associated with major infections in our patients, also reported by others previously [27, 28, 30] .
Notably, use of AZA and IVIG in the current study was independently associated with major infections after adjusting for other factors. AZA is known to cause bone marrow suppression and thus increase the incidence of infections in patients with CTDs [47] [48] [49] . The results of this study are in agreement with the literature. On the other hand, the use of IVIG was first aimed at patients with primary and secondary immune deficiencies, and the immune-modulatory actions of IVIG were recognized by previous studies [50] [51] [52] [53] . Interestingly, this series found that IVIG is associated with increased infection rate, which apparently conflicts with previous reports. However, establishing a causal relationship between infections and IVIG is difficult, given the retrospective nature of this study. The observed association between infection and IVIG use might reflect persistent disease activity rather than specific adverse effects of IVIG on PM/DM patients. Patients with more severe disease, notably including dysphagia, were more likely to be treated with IVIG. The association is with the underlying disease and not with the drug. Similarly, the association with AZA might be because of the presence of ILD and avoidance of MTX. To date, prospective controlled trials comparing the use of immunosuppressive drugs and the incidence of infections in PM/DM are still very rare. Further risk/benefit analyses of immunosuppressive agents in PM/DM patients are needed.
In this study, univariate analysis demonstrated a marked correlation between lymphopenia and major infection. However, according to multivariate analysis, lymphopenia is apparently not a relevant risk factor. Lymphopenia is a common biologic abnormality in patients with CTDs [30, [54] [55] [56] [57] . Further, researchers have established that lymphopenia is a contributing factor in the development of opportunistic infection in PM/DM, including severe and fatal infection with P. jirovecii pneumonia [11, 13, 30, [40] [41] [42] . However, lymphopenia is not necessarily associated with infection from the data at hand since the lymphocyte counts used for the analysis were from the baseline observation. Despite the controversial data in this study, we still recommend monitoring of peripheral blood lymphocyte counts during follow-up of PM/DM patients [30] .
Patients who presented with arthritis/arthralgia and had ILD were also more likely to develop major infections in this series. The possible explanation for this result is that the presence of extramuscular manifestations such as arthritis/arthralgia and ILD usually indicates increased severity of disease activity in PM/DM patients. The presence of arthritis, ILD and anti-Jo-1 antibody is not likely to be independent. A recent study indicates that antiJo-1 antibody levels correlate with joint disease activity [58] . Another study reported that patients with anti-Jo-1 antibody present with arthritis more frequently than those without [59] . These findings may support our hypothesis that arthritis/arthralgia and anti-Jo-1 antibody are related, and are therefore not independent risk factors for developing ILD [10] and major infection. Therefore, involvement of other organs and even impairment of the immune system are more common in this subgroup of PM/DM patients.
In conclusion, this series revealed a high frequency of major infections in PM/DM patients, which was also associated with reduced survival. Although aspiration pneumonia was the leading cause of major infections, opportunistic infections should be kept in mind as well. Of the various pathogens isolated, the most common micro-organisms infecting PM/DM patients were S. aureus, Klebsiella, E. coli, Salmonella and Mycobacterium. Patients who were older at the time of PM/DM onset, who presented with arthritis/arthralgia or who had ILD, tended to have a higher frequency of major infections. Additionally, timely use of immunosuppressive agents such as AZA is essential for controlling PM/DM-related complications, but judicious use of these agents is equally important for avoiding major infections.
Rheumatology key messages
. There is a high frequency of major infections in PM/ DM patients, which also associated with reduced survival. . Although aspiration pneumonia is the leading cause of major infections, opportunistic infections should be kept in mind as well.
